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Abstract
Background. Extending the administration interval of
erythropoiesis-stimulating agents (ESAs) represents an op-
portunitytoimprovetheefficiencyofanaemiamanagement
inpatientswithchronickidneydisease(CKD).However,ef-
fective haemoglobin (Hb) maintenance can be challenging
with epoetin alfa and epoetin beta administered at extended
intervals. C.E.R.A., a continuous erythropoietin receptor
activator,hasauniquepharmacologicprofileandlonghalf-
life(∼130h),allowingadministrationatextendedintervals.
Phase III results have demonstrated that C.E.R.A. admin-
istered once every 4 weeks effectively maintains stable Hb
levels in patients with CKD on dialysis.
Methods. STRIATA (Stabilizing haemoglobin TaRgets in
dialysis following IV C.E.R.A. Treatment for Anaemia)
wasamulticentre,open-labelrandomizedphaseIIIstudyto
evaluatetheefficacyandsafetyofintravenousC.E.R.A.ad-
ministered once every 2 weeks (Q2W) for Hb maintenance
following direct conversion from darbepoetin alfa (DA).
Adult patients on dialysis receiving stable intravenous DA
once weekly (QW) or Q2W were randomized (1:1) to con-
tinue their current DA regimen (n = 156) or receive intra-
venous C.E.R.A. Q2W (n = 157) for 52 weeks. Doses were
adjusted to maintain Hb levels within ± 1.0 g/dl of baseline
and between 10.0 and 13.5 g/dl. The primary endpoint was
the mean Hb change between baseline and the evaluation
period (weeks 29–36).
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Results. Most patients (>80%) received DA QW before
randomization. The mean (95% CI) difference between
C.E.R.A. and DA in the primary endpoint was 0.18 g/dl
(−0.05, 0.41), within a pre-defined non-inferiority limit.
C.E.R.A. was clinically non-inferior to DA (P < 0.0001) in
maintaining Hb levels. Both treatments were well tolerated.
Conclusions. Stable Hb levels were successfully main-
tained in patients on haemodialysis directly converted to
Q2W intravenous C.E.R.A. from DA.
Keywords: anaemia; C.E.R.A.; darbepoetin alfa; dialysis;
haemoglobin
Introduction
Anaemia secondary to chronic kidney disease (CKD) is as-
sociated with increased hospitalization and decreased sur-
vival[1,2],increasedburdenofcardiovasculardisease[3,4]
and reduced quality of life [5,6]. Despite improvements,
large observational studies such as the Dialysis Outcomes
and Practice Patterns Study (DOPPS) indicate that anaemia
remains prevalent in patients receiving dialysis; therefore,
thereisaneedtoincreasetheproportionsofpatientsachiev-
ing guideline haemoglobin (Hb) targets [7]. With the grow-
ing prevalence of CKD [8,9], new approaches are required
to improve the efficiency of anaemia management without
increasing the workload of healthcare staff.
Extended administration intervals represent an opportu-
nity to simplify treatment and improve the efficiency of
anaemia management. For example, the preliminary results
of a recent observational study indicated that extending the
administration interval from three times weekly to once
C   The Author [2008].
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weekly (QW) was associated with substantial time savings
[10]. It was estimated that 350 h of physician/nurse time
per year could besaved ina centre with50dialysis patients.
Extended administration intervals may also offer benefits
for patients with CKD. If administration intervals could be
successfully extended beyond QW for all patients, the re-
sulting time savings could enable healthcare providers to
spend more time focusing on other aspects of CKD man-
agement, including patient education, and to address other
modifiable risk factors, such as hypertension and mineral
balance.
C.E.R.A., a continuous erythropoietin receptor activa-
tor, is indicated in the European Union for once-monthly
maintenance of Hb levels in patients with CKD. C.E.R.A.
has different receptor binding characteristics to established
erythropoiesis-stimulating agents (ESAs) [11,12] and a
long half-life of ∼130 h following intravenous and sub-
cutaneous administration [13]. In phase II and phase III
studies in patients with CKD on dialysis, C.E.R.A. effec-
tively maintained stable Hb levels when administered once
every 4 weeks (Q4W) [14–16].
STRIATA (Stabilizing haemoglobin TaRgets in dialy-
sis following IV C.E.R.A. Treatment for Anaemia) was
a multicentre, open-label randomized phase III study de-
signed to investigate the efficacy and safety of intra-
venous C.E.R.A. administered once every 2 weeks (Q2W)
for Hb maintenance in patients on dialysis who con-
verted directly from darbepoetin alfa (DA) QW or Q2W.
We report the primary efficacy and safety results from
STRIATA.
Patients and methods
Patients
Adult patients with chronic renal anaemia receiving ad-
equate haemodialysis (Kt/V ≥1.2 or urea reduction ratio
≥ 65%) or peritoneal dialysis (weekly Kt/V ≥1.8) for
≥12weeksandintravenousDAtherapyatthesameadmin-
istration interval (either QW or Q2W) for ≥8 weeks were
eligible for screening.
Patients had stable mean baseline Hb levels (difference
between mean individual Hb values at the beginning and
end of the run-in period ≤1 g/dl) of between 10.5 and
13.0 g/dl. The values for Hb entry criteria were within the
ranges recommended by anaemia treatment guidelines at
the time the study was designed [17,18]. Adequate iron
status (serum ferritin ≥100 ng/ml or transferrin saturation
≥20% or hypochromic red cells <10%) was also required
for study entry.
Patients were excluded if they had non-renal causes of
anaemia(e.g.folicacidorvitaminB12 deficiency,haemoly-
sis and haemoglobinopathies), C-reactive protein >30 mg/l
or life expectancy <12 months.
The study was conducted in accordance with the Decla-
ration of Helsinki, International Conference on Harmoni-
sation Good Clinical Practice guidelines and was approved
by local ethics committees. All study participants provided
written informed consent.
Study drugs
C.E.R.A. (F. Hoffmann-La Roche Ltd, Basel, Switzerland)
was provided as a sterile injectable solution in 2 ml single-
use glass vials containing 1 ml solution. The solution was
available in 50, 100, 200, 400 and 1000 µg/ml concentra-
tions.
DA (Amgen Inc., Thousand Oaks, USA) was obtained
commercially in pre-filled syringes.
Study design
STRIATA was a multicentre, parallel-group, open-label,
randomized phase III study designed to investigate the ef-
ficacy and safety of intravenous C.E.R.A. Q2W for Hb
maintenance in patients on dialysis who converted directly
from intravenous DA QW or Q2W.
After a 4-week run-in period during which patients con-
tinued to receive DA, patients were randomized (1:1) to
receive intravenous C.E.R.A. Q2W or to continue their in-
travenous DA regimen (Figure 1). Patients were randomly
assigned to one of the two treatment groups by a central
randomization centre. For each study centre, randomiza-
tion numbers were allocated sequentially to each patient in
the order in which they were enrolled.
The starting doses of C.E.R.A. were selected based on
the results of phase II studies and calculated by patient
according to their DA dose before randomization (Table 1).
A period of 28 weeks after the first dose of study drug was
used for dose titration. This was followed by an 8-week
efficacy evaluation period (weeks 29–36), and a further 16-
week safety observation period (weeks 37–52; Figure 1).
Duringthedose-titrationandevaluationperiods,dosesof
trial medication were adjusted according to Hb response.
The aim was to maintain individual patients’ Hb within
±1.0 g/dl of their baseline level, and to maintain absolute
Baseline
period
Titration
period
Evaluation
period
Safety
period
4 weeks 28 weeks 8 weeks 16 weeks
C.E.R.A. Q2W
DA QW or Q2W
R
DA
QW or Q2W
Fig. 1. Study design. DA, darbepoetin alfa; R, randomization; QW, once
weekly; Q2W, once every 2 weeks.
Table 1. Starting doses of C.E.R.A.
Previous DA dosage C.E.R.A. starting dosage
(µg/week) (µg/2 weeks)
<40 60
40–80 100
>80 180
DA, darbepoetin alfa.3656 B. Canaud et al.
Hb values for the overall study population between 10.0
and 13.5 g/dl. During the safety observation period, doses
were adjusted to maintain the Hb levels within 11–13 g/dl.
It should be noted that the target Hb ranges chosen for this
study were agreed by consensus of the Steering Committee
based on contemporary anaemia treatment guidelines; the
study was completed before the publication of the CHOIR
study which prompted safety concerns regarding the main-
tenance of Hb levels >13 g/dl [19].
Dose adjustments were permitted for safety at any point
duringthestudy.Unlesssafetyconcernsdictatedotherwise,
dose adjustments were performed at the next scheduled
dosing day so that the administration interval remained un-
changedthroughoutthestudy.Inaddition,doseadjustments
forC.E.R.A.werenotperformedmorefrequentlythanonce
every 4 weeks. Dose adjustments for DA were performed
according to its approved labelling (i.e. 25% dose increase
or decrease based on the Hb value), but maintaining the tar-
get Hb and the interval between dose adjustments the same
as for C.E.R.A. Patients received intravenous iron supple-
mentation as required throughout the run-in and treatment
periods.
Study parameters
The primary efficacy parameter was the change in mean
Hb levels between baseline and the evaluation period. Sec-
ondary efficacy parameters were the proportion of patients
maintaining Hb within ± 1 g/dl of baseline during the eval-
uation period and the incidence of red blood cell (RBC)
transfusions during the dose-titration and evaluation pe-
riods. Additional efficacy parameters included mean Hb
over time, mean Hb by study period, intrapatient Hb vari-
ability (mean within-patient standard deviations for Hb)
during the dose titration, evaluation and safety observa-
tion periods and the number of patients requiring dose ad-
justments. Safety parameters included adverse event (AE)
reporting, vital signs, laboratory haematology and blood
chemistry (including iron), immunogenicity testing and
electrocardiograms.
Assessments
Patients were assessed weekly during the screening/
baseline, dose-titration and evaluation periods, and every
other week during the safety observation period. Hb lev-
els, blood pressure, heart rate, iron status and other safety
laboratory parameters were assessed throughout the study.
Blood samples were collected for anti-erythropoietin an-
tibody testing at weeks 1, 13, 29 and 41 and at the final
visit.
AEs were recorded during the randomized treatment pe-
riod and RBC transfusions and iron supplementation were
recorded throughout the study.
Statistical analysis
A sample size of 264 patients (≥132 patients per treatment
group) was required to test with 90% power the hypoth-
esis that C.E.R.A. Q2W was non-inferior to DA (primary
efficacyparameter).Thisassumesatruedifferencebetween
the C.E.R.A. and DA groups not greater than 0.3 g/dl, a
common standard deviation for both groups of 1.0 g/dl and
a drop-out/major protocol violation rate of 20%.
Non-inferiority was tested by calculating the difference
in the primary efficacy parameter (mean Hb change be-
tween baseline and the evaluation period) for patients ran-
domized to treatment with C.E.R.A. and DA. Two-sided
95%confidence intervals(CIs)forthisdifferencewerecal-
culated by analysis of covariance (ANCOVA), using treat-
ment group as the independent variable and adjusting for
covariates that might influence Hb response (baseline Hb
and geographic region). Non-inferiority of C.E.R.A. versus
DA could be concluded if the lower limit of the 95% CI
was ≥−0.75 g/dl. In setting the −0.75 g/dl Hb threshold
for the lower limit of the 95% CI (around the mean group
difference), it was expected that the observed mean differ-
ence between the groups would be markedly <0.75 g/dl
(according to the anticipated level of variability) and at a
level not regarded as being clinically significant.
The primary efficacy analysis was conducted on the per-
protocol (PP) population (patients without major protocol
violations or withdrawal) and was confirmed on the intent-
to-treat (ITT) population (all randomized patients).
Secondary and additional efficacy analyses were per-
formed on the ITT population and summarized using de-
scriptive methods. The last observation carried forward
approach was used for missing data. In the case of RBC
transfusions, the Hb value measured before the transfu-
sion was used. Safety assessments, which included AE
reporting, laboratory assessments of iron parameters and
blood chemistry and monitoring of vital signs, were ex-
amined in the safety population (all patients who received
at least one dose of study medication and had a safety
follow-up assessment), and group summary statistics were
calculated.
Results
Patients
Patients were recruited from 48 centres in 12 countries in
Europe, Australia and Canada. The disposition of enrolled
patients is shown in Figure 2. The ITT population com-
prised313patientswhowererandomizedtoC.E.R.A.Q2W
(n=157)orDAattheircontinuedweeklydoseandinterval
(n = 156). The PP population comprised 249 patients.
The main reasons for exclusion from the PP population
were less than five Hb values measured during evaluation
(n = 37), inadequate iron status at baseline and during
evaluation or no valid iron assessments (n = 29) and RBC
transfusions within weeks 20–32 (n = 17). In addition, four
patients in the C.E.R.A. group withdrew before receiving
any study medication [protocol violation (n = 1), refused
treatment (n = 1), failed to return (n = 2)] and were not
included in the safety population.
Most patients (n = 249) completed the study. Reasons
for premature withdrawal from the study included death
(12 and 10 patients in the C.E.R.A. and DA groups, re-
spectively), transplantation (14 and 6 patients treated with
C.E.R.A. and DA, respectively), refusal of treatment (fourSTRIATA haemoglobin maintenance in patients on dialysis 3657
Summary of patient withdrawals
(ITT population)
Due to AE,    n = 1
Due to death,  n = 12
Non-safety reason ,  n = 26
†
Summary of patient withdrawals
(ITT population)
Due to AE,    n = 1
Due to death,  n = 10
Non-safety reason ,  n = 14
†
DA
QW or Q2W
Screened n = 444
DA QW or Q2W
Safety,  n = 156
ITT,  n = 156
PP,  n = 126
C.E.R.A. Q2W
Safety,  n = 153
ITT,  n = 157
PP,  n = 123
Fig. 2. Patient populations and disposition. †Non-safety reasons were
kidney transplantation (C.E.R.A., n = 14; DA, n = 6), refusal of treatment
(C.E.R.A., n = 4; DA, n = 3) and failure to return (C.E.R.A., n = 2).
The remaining 11 patients (C.E.R.A., n = 6; DA, n = 5) withdrew for
reasons that included patient vacation, patient decision, patient instability
(poor medical condition), protocol violation, discontinuation of dialysis,
enrolled in nocturnal haemodialysis study and starting home dialysis. DA,
darbepoetinalfa;QW,onceweekly;Q2W,onceevery2weeks;ITT,intent-
to-treat; PP, perprotocol; AE, adverse event.
patients in the C.E.R.A. group and three patients in the DA
group) and AEs (one patient in each group).
Baseline characteristics were similar between treatment
groups (Table 2) and were generally representative of the
dialysis population. The primary causes of CKD in each
treatment group were diabetes (24.0%), glomerulonephri-
tis (23.0%) and hypertension/large vessel disease (21.4%)
(Table 2). Before randomization, 82.2% of patients in the
C.E.R.A. group and 84.0% DA group were receiving DA
at weekly intervals (Table 2). There were slightly more
male patients in the C.E.R.A. group (Table 2). Mean Hb
levels at baseline were similar in patients randomized to
C.E.R.A. (12.0 g/dl) and DA (11.9 g/dl). Most patients
were undergoing haemodialysis with arteriovenous fistula
for vascular access and had been receiving dialysis for
∼3.5 years (Table 2); one patient was receiving peritoneal
dialysis (DA group). Arteriovenous grafts and catheters
were slightly more common in the DA group (Table 2).
Similar proportions of patients in each group received
angiotensin-converting enzyme inhibitors and angiotensin-
II receptor antagonists.
Efficacy evaluation
Mean Hb levels during the evaluation period were similar
between treatment groups (Table 3; Figure 3): 12.1 g/dl
for C.E.R.A. and 11.8 g/dl for DA (Table 3). Adjusted
mean changes in Hb between baseline and the evaluation
period (PP population) were 0.06 g/dl for C.E.R.A. and
−0.12 g/dl for DA with the mean (95% CI) difference
between groups being 0.18 g/dl (−0.05, 0.41) (Figure 4).
The lower limit of the 95% CI was considerably greater
than the pre-defined −0.75 g/dl non-inferiority threshold,
demonstrating that C.E.R.A. was non-inferior to DA for
the maintenance of Hb levels (P < 0.0001). Comparable
results were obtained when the test was repeated in the ITT
population (Figure 4).
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Non-inferiority
lower 95% CI limit
Difference in mean adjusted Hb change, g/dl
PP
ITT
0.18
-0.05 0.41
0.29
0.02 0.55
-1.00 -0.75 -0.50 -0.25 0.00 0.25 0.50 0.75 1.00
Fig. 4. Non-inferiority test for treatment differences. CI, confidence in-
terval;ITT,intent-to-treat;PP,per-protocol;Hb,haemoglobin.P<0.0001
for both comparisons.
Duringtheevaluationperiod,meanHbvaluesweremain-
tained within +1 g/dl of baseline in a similar proportion of
patients treated with C.E.R.A. and DA (65.5 and 71.8%
of patients in the C.E.R.A. and DA groups, respectively,
P = 0.2502, chi-square test). Assessment of the mean stan-
dard deviation of Hb revealed similar intrapatient Hb vari-
ability in the C.E.R.A. and DA groups during the titration
(0.86 versus 0.76 g/dl), evaluation (0.63 versus 0.53 g/dl)
and safety observation (0.71 versus 0.66 g/dl) periods
(Figure 5). These findings are consistent with the primary
efficacy assessment and support the view that Hb con-
trol was successfully maintained following conversion to
C.E.R.A. in patients who were predominantly (>80%) re-
ceiving QW DA before randomization.
Iron parameters were well maintained in both treatment
groups (Table 4). Concomitant iron supplementation was
administered to 92% of patients treated with C.E.R.A. and
93% of those receiving DA. The most frequently used iron
supplements were iron sucrose and ferrous gluconate.
SimilarproportionsofpatientsrequiredatleastoneRBC
transfusionduringthedose-titrationandevaluationperiods:
C.E.R.A. (12.4%) and DA (10.3%).
Assessment of doses of trial medication revealed that
baseline median doses were 0.49 µg/kg/week [interquartile
range(IQR):0.43–0.73]forC.E.R.A.and0.44µg/kg/week3658 B. Canaud et al.
Table 2. Baseline characteristics (intent-to-treat population)
C.E.R.A. (n = 157) DA (n = 156)
Male, n (%) 100 (64) 81 (52)
Mean age, year (± SD) 62.4 (16.17) 61.8 (14.74)
Mean weight, kg (± SD) 68.9 (16.69) 70.32 (16.50)
Mean Hb, g/dl (± SD) 12.0 (0.7) 11.9 (0.7)
Median TSAT, % (IQR) 28.4 (22.3–35.3) 28.0 (21.6–33.5)
Median ferritin, µg/l (IQR) 367.8 (216–547) 382.3 (233–596)
Primary cause of CKD (incidence ≥5%) (%)
Diabetes 25 22
Glomerulonephritis 25 21
Hypertension/large vessel disease 24 19
Interstitial nephritis/pyelonephritis 8 16
Undefined aetiology 6 9
Secondary glomerulonephritis/vasculitis 6 6
Polycystic kidney disease 4 5
Other hereditary/congenital disease 5 <1
Previous DA schedule, n (%)
QW 129 (82.2) 131 (84.0)
Q2W 28 (17.8) 25 (16.0)
Mean Kt/Va (± SD) 1.57 (0.33) 1.57 (0.34)
Vascular access type, n (%)
Arteriovenous fistula 132 (84.1) 117 (75.5)
Arteriovenous graft 18 (11.5) 26 (16.8)
Indwelling (tunnelled) catheter 7 (4.5) 12 (7.7)
Median time since first dialysis (days) 1254 1319
aSafety population.
DA, darbepoetin alfa; SD, standard deviation; Hb, haemoglobin; TSAT, transferrin saturation; IQR, interquartile range; CKD, chronic kidney disease;
QW, once weekly; Q2W, once every 2 weeks.
Table 3. Mean Hb by study period (per-protocol population)
Period n Mean (SD) Hb level (g/dl)
Baseline (weeks −4t o0 )
C.E.R.A. 123 12.0 (0.7)
DA 126 11.9 (0.6)
Titration (weeks 0 to 28)
C.E.R.A. 123 12.3 (0.7)
DA 126 11.9 (0.7)
Evaluation (weeks 29 to 36)
C.E.R.A. 123 12.1 (1.0)
DA 126 11.8 (1.0)
Safety (weeks 37 to 52)
C.E.R.A. 120 11.7 (1.1)
DA 124 11.7 (1.0)
DA, darbepoetin alfa; Hb, haemoglobin; SD, standard deviation.
Table 4. Medianferritinandtransferrinsaturationbystudyperiod(safety
population)
Period Median (IQR) Median (IQR)
ferritin (ng/ml) TSAT (%)
Baseline (weeks −4t o0 )
C.E.R.A. 368 (216–543) 28.2 (22.0–35.0)
DA 382 (231–596) 28.0 (21.9–33.5)
End of evaluation (week 36)
C.E.R.A. 357 (223–569) 29.0 (22.5–36.7)
DA 402 (251–635) 25.9 (21.0–32.0)
End of study (week 52)
C.E.R.A. 405 (282–614) 25.9 (21.0–32.0)
DA 400 (241–577) 25.8 (19.5–34.0)
DA, darbepoetin alfa; IQR, interquartile range; TSAT, transferrin satura-
tion.
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Fig. 5. Individual stability of Hb mean levels (intent-to-treat popula-
tion). No formal test was conducted to assess the statistical significance
of between-group differences; however, the overlapping SD bars sug-
gest any difference would not be significant. DA, darbepoetin alfa; QW,
once weekly; Q2W, once every 2 weeks; Hb, haemoglobin; SD, standard
deviation.
(0.27–0.69) for DA. During the evaluation period, the me-
dian dose in the C.E.R.A. group was 0.35 µg/kg/week
(0.19–0.54): this remained stable at the end of the study
[0.35 µg/kg/week (0.16–0.58)]. The median dose of DA
was 0.40 µg/kg/week (0.25–0.74) during the evaluation pe-
riod and 0.44 µg/kg/week (0.28–0.81) at the end of the
study. Similar proportions of patients (90.2% C.E.R.A. and
89.7% DA) required adjustments in the dose of study med-
ication. The median (IQR) number of dose adjustments per
patient throughout the entire study period was 6 (3–9) in
the C.E.R.A. group and 5 (3–9) in the DA group.STRIATA haemoglobin maintenance in patients on dialysis 3659
Table 5. Overall and most frequent adverse events (≥8% of patients)
(safety population)
Number (%)
C.E.R.A. DA
(n = 153) (n = 156)
Diarrhoea 24 (16) 16 (10)
Nasopharyngitis 19 (12) 16 (10)
Influenza 19 (12) 12 (8)
Fluid overload 14 (9) 13 (8)
Cough 14 (9) 12 (8)
Hypertension 13 (8) 12 (8)
Back pain 11 (7) 13 (8)
Vomiting 10 (7) 13 (8)
Upper respiratory tract infection 9 (6) 12 (8)
Headache 8 (5) 12 (8)
Angina pectoris 12 (8) 7 (4)
Pyrexia 12 (8) 6 (4)
Any adverse event 135 (88.2) 143 (91.7)
Serious adverse events 71 (46.4) 75 (48.1)
Adverse events leading to withdrawal 1 (0.7) 1 (0.6)
Deathsa 13 (8.5) 12 (7.7)
aIncludes three deaths of patients who had been withdrawn for other
reasons.
DA, darbepoetin alfa.
Safety and tolerability
The overall incidences of AEs, serious AEs and AEs lead-
ing to withdrawal and deaths were similar between the
two treatment groups and typical of the patient population
(Table5).AtleastoneAEwasexperiencedby88%and92%
of patients in the C.E.R.A. and DA groups, respectively, al-
though most events were mild or moderate in intensity. The
most commonly reported AEs were diarrhoea, nasopharyn-
gitis and influenza (Table 5). AEs leading to withdrawal
occurred in one patient in each treatment group (hyperten-
sive encephalopathy in the C.E.R.A. group and peripheral
ischaemia in the DA group).
Serious AEs were experienced by 46% and 48% of pa-
tients in the C.E.R.A. and DA groups, respectively. Serious
AEs were considered to be related to study treatment in one
patient in the C.E.R.A. group (arteriovenous graft throm-
bosis) and three patients in the DA group (arteriovenous
graft thrombosis, arteriovenous fistula site haemorrhage
and cerebral infarction).
Twenty-five deaths occurred in the study (13 C.E.R.A.
patients and 12 DA patients; Tables 5 and 6), including
three deaths of patients who had been withdrawn for other
reasons (one patient in the C.E.R.A. group and two pa-
tients in the DA group). None of these deaths were con-
sidered to be related to study treatment. Table 6 shows all
causes of death during the study. It should be emphasized
that the majority of deaths in patients treated with both
C.E.R.A. and DA were associated with maximum Hb lev-
els <11 g/dl within the 2 weeks before death.
There were no clinically relevant changes in vital signs
or laboratory parameters during the study period. Study
drug-related antibodies were not detected in any patient.
Table 6. Listing of all deaths during the study ranked by maximum Hb
level within the 2 weeks before death (safety population)
Maximum Hb within Cause of death
previous 2 weeks (g/dl) (randomization group)
8.5 Cachexia (DA)
8.7 Malignant lung neoplasm (C)
8.8 Sepsis (DA)
8.9 Cardio-respiratory arrest (C)
9.5 Cachexia (DA)
9.7 Septic shock (C)
10.3a Infection (DA)
10.8 Sepsis (C)
10.5 Chronic renal failure (DA)
10.6 Chronic renal failure (DA)
10.6 Atherosclerosis (C)
10.8 Cardiac arrest (DA)
11.0 Myocardial infarction (C)
11.3 Sudden death (C)
11.6 Pneumonia (C)
12.0 Calciphylaxis (C)
12.1 Cardiac arrest (DA)
12.1 Cerebrovascular accident (DA)
12.1 Enterococcal sepsis (DA)
12.2 Pneumonia aspiration (DA)
12.6 Cardiopulmonary failure (C)
12.9 Cerebrovascular accident (DA)
14.8 Ventricular fibrillation (C)
14.9 Intestinal infarction (C)
15.6 Cerebral haemorrhage (C)
aMaximum Hb level within the 4 weeks before death. Light shading
denotes maximum Hb levels <11 g/dl within the 2 weeks before death;
no shading denotes maximum Hb levels between 11 and 12 g/dl; dark
shading maximum Hb levels >12 g/dl.
C, C.E.R.A.; DA, darbepoetin alfa.
Discussion
These findings from STRIATA demonstrate that patients
receiving haemodialysis can be successfully converted to
Q2W intravenous C.E.R.A. from intravenous DA main-
tenance therapy. In addition, the results confirm that the
simple dosing conversion scheme based on previous DA
dose was effective in providing stable Hb maintenance for
patients converting from DA to Q2W C.E.R.A. Patients in
STRIATA successfully maintained mean Hb levels within
the 10.0–13.5 g/dl target range, with the primary efficacy
analysis demonstrating non-inferiority of C.E.R.A. relative
to DA (P < 0.0001) for Hb maintenance in patients receiv-
ing dialysis.
Important features of this study are the randomized,
parallel-group design and the inclusion of patients with
considerable co-morbidities, which can be considered rep-
resentative of the general dialysis population. The study
design was conceived and developed with the intention of
testing the hypothesis that intravenous C.E.R.A. is non-
inferior to intravenous DA for Hb maintenance in patients
ondialysis.Thestudyrecruitedpatientswhohadundergone
previous anaemia treatment to Hb levels within the target
ranges recommended by contemporary guidelines [17,18],
and the aim was to maintain Hb levels within similar target
ranges following randomization.
Since the completion of STRIATA, new evidence has
become available which has prompted safety concerns over3660 B. Canaud et al.
t h et a r g e t i n go fH bl e v e l s>13 g/dl [19,20]. While no cor-
relations between Hb concentrations and safety outcomes
were observed in STRIATA, the study was not designed
to address such questions. The results from STRIATA sug-
gestthatQ2WintravenousC.E.R.A.canmaintainHblevels
within a specified target range as effectively as intravenous
DA.
During the evaluation period, Hb was maintained
within ±1 g/dl of baseline in approximately two-thirds of
patients, and intrapatient Hb variability, a measure of in-
dividual stability of Hb levels, was comparable between
treatment groups during the titration, evaluation and safety
observation periods. It is noteworthy that while patients in
the reference group, who had previously been maintained
on DA, continued to be successfully maintained, those pa-
tients randomized to C.E.R.A. also maintained stable Hb
levels despite the change in therapy and, in most patients,
treatment interval.
RBC transfusions, which were assessed as a secondary
efficacy parameter, were low and similar across treatment
groups supporting the non-inferiority result obtained in the
primaryefficacyanalysis.Theobservedtransfusionratesof
10–12% are consistent with those reported by other inves-
tigators in a similar patient population [21]. C.E.R.A. was
generally well tolerated, with a similar safety profile to that
of DA. Most AEs were considered to be unrelated to study
medication and were consistent with common AEs associ-
atedwiththispatientpopulation.Consideredtogether,these
findings indicate that Q2W intravenous C.E.R.A. offers
comparable Hb control with similar safety and tolerability
to the comparator DA.
AnaemiaisacommoncomplicationofCKD,anddespite
advances in care since the introduction of the first ESAs,
further improvements in the proportions of patients achiev-
ing and maintaining guideline targets for Hb concentration
are still possible [7,22]. Moreover, within the context of
clinical practice, there is a need to optimize the efficiency
of anaemia management to ensure that nephrology clinics
can continue to provide effective care for a growing patient
population. One approach to realizing such efficiency is to
reduce the administration frequency of ESAs. Preclinical
and pharmacokinetic studies indicate that the pharmacoki-
neticandpharmacodynamicprofileofC.E.R.A.mayenable
administration at extended intervals [12,13]. This hypoth-
esis is supported by the results from STRIATA, as well as
other phase III [15,16] and phase II [14] clinical studies, in
which intravenous and subcutaneous C.E.R.A. effectively
maintainedHblevelsinpatientswithCKDondialysiswhen
administered Q4W.
In summary, results from STRIATA confirm that stable
Hb levels can be maintained with comparable variability in
patients with CKD on haemodialysis who convert to intra-
venous C.E.R.A. Q2W from intravenous DA QW or Q2W.
The time savings estimated to arise from reductions in ad-
ministration frequency [10] could represent an important
benefit in clinical practice, facilitating greater efficiency of
anaemia management and enabling healthcare providers to
devote more time to other aspects of patient care. Although
the debate surrounding optimal Hb targets is ongoing and
further evolution of anaemia treatment guidelines is antici-
pated, the findings from STRIATA should offer confidence
that intravenous C.E.R.A. can maintain stable Hb levels
within a pre-specified target range.
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